HETIAN, China, Nov. 30, 2024 /PRNewswire/ — On November 27, news came from Hetian Power Supply Company of State Grid Xinjiang Electric Power Co., Ltd. Ltd. that in order to ensure safe and reliable power supply in winter, the company laid out in advance and took active actions to provide a solid guarantee for residents in the Hotan area to spend the warm winter through a series of effective measures.
Before winter, Hetian Power Supply Company of State Grid Xinjiang Electric Power Co., Ltd. attached great importance to warmth and supply, and organized a professional team to conduct centralized inspection and live inspection of key lines. The inspection covered the main power supply lines in the Hotan area. Through careful inspection and scientific testing, more than 1,200 safety hazards were successfully investigated and managed, and 203 distribution transformers were replaced.
At the end of October, the company fully completed the 2024 rural power grid consolidation and upgrading project in Hotan area. The project has a total investment of 460 million yuan, and plans to build and renovate 1027.66 kilometers of high and low voltage distribution lines, add and replace 632 distribution transformers, and complete the installation of tables for 3316 “coal to electricity” users.
Hetian Power Supply Company of State Grid Xinjiang Electric Power Co., Ltd. has taken a series of effective measures through advance planning and active actions to provide strong support for the safety and warmth of residents in the Hotan area in winter.
ข่าวที่เกี่ยวข้อง
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
- 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
